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NADPH oxidases (Nox) represent a family of hetero-oligomeric enzymes whose exclusive biological
function is the generation of reactive oxygen species (ROS). Nox-derived ROS are essential modulators of
signal transduction pathways that control key physiological activities such as cell growth, proliferation,
migration, differentiation, and apoptosis, immune responses, and biochemical pathways. Enhanced for-
mation of Nox-derived ROS, which is generally associated with the up-regulation of different Nox sub-
types, has been established in various pathologies, namely cardiovascular diseases, diabetes, obesity,
cancer, and neurodegeneration. The detrimental effects of Nox-derived ROS are related to alterations in
cell signalling and/or direct irreversible oxidative damage of nucleic acids, proteins, carbohydrates, and
lipids. Thus, understanding of transcriptional regulation mechanisms of Nox enzymes have been ex-
tensively investigated in an attempt to ﬁnd ways to counteract the excessive formation of Nox-derived
ROS in various pathological states. Despite the numerous existing data, the molecular pathways re-
sponsible for Nox up-regulation are not completely understood. This review article summarizes some of
the recent advances and concepts related to the regulation of Nox expression in the vascular patho-
physiology. It highlights the role of transcription factors and epigenetic mechanisms in this process.
Identiﬁcation of the signalling molecules involved in Nox up-regulation, which is associated with the
onset and development of cardiovascular dysfunction may contribute to the development of novel
strategies for the treatment of cardiovascular diseases.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Evidence from the last two decades in the ﬁeld of redox biologyB.V. This is an open access article u
.have led to a profound change of the dogma that reactive oxygen
species (ROS) are detrimental to cells and are predominantly
produced as by-products of cellular metabolism and respiration.
Since the discovery of vascular NADPH oxidase (Nox) in the late
90s, it has become the focus of continual and extensive research
interest due to its exclusive function to produce ROS under normalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Role of Nox-derived ROS signalling in atherosclerosis. Nox are important sources of ROS in the vascular cells and in immune cells interacting with the blood vessels.
The diagram shows the distinct expression of Nox subtypes in the cells involved in atheroma formation: endothelial cells (EC), smooth muscle cells (SMC), adventitial
ﬁbroblasts, monocytes (Mon), macrophages and foam cells (Mac), T lymphocytes (TLy), platelets (Pl), and mast cells (Mast). Activation of speciﬁc signalling pathways by
cardiovascular risk factors determines up-regulation of Nox and the ensuing ROS production. Nox-derived ROS play an important role in the regulation of signal transduction
and gene expression by activating redox-sensitive transcription factors and epigenetic constituents. Persistent Nox activation induces oxidative stress, a major contributor to
atherosclerotic lesions initiation and development.
S.-A. Manea et al. / Redox Biology 5 (2015) 358–366 359physiological conditions. Yet, enhanced formation of Nox-derived
ROS, which is generally associated with the up-regulation of its
expression, has been reported in numerous pathologies such as
cardiovascular diseases, cancer, diabetes, obesity, and neurode-
generative disorders. Thus, this activity is currently considered as
key pathological trigger of oxidative stress-induced cellular dele-
terious effects [1–4]. Recently, the ﬁrst class of Nox1 and Nox4
pharmacological inhibitors, GKT137831, received the approval for
phase II clinical study for the treatment of diabetic nephropathy
[5,6]. Similarly, beneﬁcial effects of GKT137831 in attenuating
oxidative stress-induced vascular injury were reported in experi-
mental models of diabetes-accelerated atherosclerosis [7]. Thus, it
has become rapidly evident that understanding of the molecular
mechanisms implicated in the regulation of Nox expression and
function represents a prerequisite to counteract ROS-induced cell
damage and ultimately to prevent organ failure in a large number
of pathologies.
Nox has been initially characterized in professional phagocytes,
as burst enzyme, having a critical role in the killing the invading
pathogens. Structurally, the phagocyte-type Nox contains a
membrane-associated protein complex, known as cytochrome
b558, comprising the gp91phox/Nox2 and p22phox components,
and three cytosolic regulatory subunits (i.e., p40phox, p47phox,
and p67phox). In resting cells the Nox complex is dissociated
(inactive state) but is rapidly assembled into an active O2--gen-
erating oxidase following the exposure of the phagocytic cells to
microbes. Two functionally-related regulatory proteins have been
described in non-phagocytes, including Nox organizer 1 (Noxo1)
and Nox activator 1 (Noxa1). Later, after its functional character-
ization in the immune cells, several structurally related but func-
tionally distinct Nox subtypes were identiﬁed in numerous non-
phagocytic cells including vascular cells. In addition to the arche-
typical Nox2 phagocyte-type Nox, the oxidase family also com-
prises Nox1, Nox2, Nox3, Nox4, Nox5, Duox1, and Duox2 isoforms;
each of these having a speciﬁc function and a distinct pattern of
intracellular compartmentalization and tissue distribution [8].Although it has been extensively demonstrated that the ex-
pression of various Nox proteins and ROS production are upregu-
lated by pro-inﬂammatory cytokines, growth factors, hormones,
vasoactive agents, metabolic intermediates, modiﬁed lipids and
lipoproteins in different cardiovascular cells [9–12], the molecular
mechanisms involved in these processes have remained elusive.
This review brieﬂy summarizes and discusses some of the latest
concepts on the regulation of Nox expression in vascular patho-
physiology, emphasizing the role of transcription factors and epi-
genetic mechanisms.
Multiple ways of Nox activation have been described in various
cell types under normal and pathological states. These include the
phosphorylation of cytosolic regulatory subunits by protein kinase
C (PKC), protein kinase A (PKA), phosphatidylinositol-3-kinase
(PI3K), mitogen-activated protein kinases (MAPK), and non-re-
ceptor associated protein kinases (e.g., JAK and SRC) [13–18]. Also,
protein–protein interactions among Nox and members of the
thioredoxin family and transient oscillations in intracellular con-
centration of various ions may trigger the activation of Nox [19–
21]. Hitherto, enhanced level of NADPH oxidase expression has
been increasingly implicated as essential mechanisms responsible
for excessive and sustained release of ROS in the non-phagocytic
cells.Regulation of Nox enzymes by transcription factors and nuclear
receptors
Accumulating evidence suggests that the extent of Nox-driven
ROS formation is closely dependent on the level of its expression
level [22]. Thus, in addition to direct activation of Nox by phos-
phorylation-dependent pathways, other mechanisms linked to the
regulation of Nox expression have been described. These may in-
clude a large spectrum of transcription factors, molecules inﬂu-
encing mRNA stability, and various epigenetic processes such as
DNA methylation, post-translational modiﬁcation of histones, and
S.-A. Manea et al. / Redox Biology 5 (2015) 358–366360non-coding RNA [23].
Different Nox enzymes are constitutively expressed in vascular
cells (e.g., endothelial cells, smooth muscle cells, ﬁbroblasts, and
pericytes), cardiac myocytes, and in circulating and tissue-resident
immune cells (e.g., monocytes, macrophages, dendritic cells, and
mast cells). Whereas low level of Nox expression and activity was
detected under normal physiological conditions, the up-regulation
of the various Nox subtypes has been associated with innate and
adaptive immune reactions, as well as in vascular wall cells re-
sponse to injury underlying atherosclerosis, diabetes, obesity, hy-
pertension, and hypoxia [9,24–26] (Fig. 1). Therefore, under-
standing the molecular transcriptional machinery that controls
Nox expression may provide important clues about the role of
redox signalling, and in particular of Nox enzymes, in mediating
key biological activities in the immune and cardiovascular systems
which are often interconnected.
In previous studies others and we have shown the presence of
typical TATA boxes within the core promoter regions of several
Nox subunits. TATA cis-acting regulatory elements mediate the
recruitment of RNA polymerase II following the formation of a
multi-component protein complex formed of various transcription
factors such as TFIID, TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH. The for-
mation of the RNA polymerase II – TFII-type transcription factors
complex, also known as basal transcriptional complex, is re-
sponsible for the constitutive expression of members of the Nox
family in different cell types. Besides TATA binding proteins, sev-
eral other DNA elements, such as CCAC and GAGA boxes that may
contribute to the basal promoter activity, were predicted by in
silico analysis within the proximal promoters of the human Nox
genes [27].
Nox-derived ROS play an important role in the innate immune
response, which is the ﬁrst to react against invading pathogens,
but is also crucially involved in regulating the adaptive arm of the
immune response. For example, defects in the genes encoding for
Nox2/gp91phox (CYBB), p22phox (CYBA), p47phox (NCF1) or
p67phox (NCF2) subunits cause a rare inherited immune disorder
called chronic granulomatous disease characterized by impaired
defense mechanisms against infection. Nox is rapidly activated and
its expression is enhanced in professional phagocytes subsequent
to microbial infections [28]. Consequently, numerous studies have
focused on the role of speciﬁc transcription factors that could
mediate these effects.
In addition, Nox-derived ROS have been implicated in the
regulation of critical signalling pathways associated with the im-
munologic synapse, controlling the adaptive immune responses in
relation to antigen processing and presentation by professional
antigen presenting cells. Thus, the transcriptional regulatory me-
chanisms of the various components comprising the prototypical
Nox (i.e., Nox2/gp91phox, p22phox, p47phox, and p67phox) have
been extensively investigated in lymphocytes, dendritic cells, and
myelomonocytic cells such as monocytes, monocyte-derived
macrophages and polymorphonuclear leukocytes (e.g., neu-
trophils) in an attempt to decipher the link between the expres-
sion and function of Nox in immune cells [29–32]. Among the
different transcription factors that regulate the expression of
Nox2/gp91phox, p22phox, p47phox, and p67phox subunits, PU.1,
Elf-1, interferon regulatory factor-1 (IRF-1), and interferon con-
sensus sequence binding (ICSBP) were the most investigated
[33,34]. Besides these positive-acting transcriptional regulatory
mechanisms, several negative regulators of Nox (i.e., p67phox
subunit) expression have been demonstrated in myeloid cells, in-
cluding HoxA1 that acts in concert with histone deacetylase 2
(HDAC2) [35]. PU.1 transcription factor interacts with a speciﬁc
purine-rich DNA element in the promoter and enhancer of target
genes hence inﬂuencing key biological processes in the immune
system such as differentiation and activation of macrophages, andmaturation of B-cells [36]. Transcriptional regulation of interferon
(IFN)-inducible genes mediating the anti-viral and anti-bacterial
immune response require the activation of IRF-1 and ICSBP bind-
ing proteins that up-regulate the levels of a number of molecules
linked to anti-viral (e.g., IFNα/β), antibacterial defense (e.g., in-
ducible NO synthase), as well as anti-proliferative action, and DNA
damage/repair responses [37,38].
In addition to Nox, these transcription factors also regulate
important genes associated with differentiation, proliferation, and
migration of immune cells, and control the expression of a ple-
thora of pro-inﬂammatory and immune factors such as cytokines,
chemokines, growth factors, immunoglobulins and im-
munoglobulin receptors, and macrophage-speciﬁc scavenger re-
ceptors [36]. These ﬁndings suggest a strong and direct correlation
between Nox up-regulation and inﬂammatory/immune reactions.
Several transcription factors have been identiﬁed as critical
regulators of pro-inﬂammatory reactions in the vasculature in-
cluding nuclear factor kB (NF-kB), activator protein 1 (AP-1), and
members of the signal transducer and activator of transcription
(STAT) and CCAAT-enhancer binding proteins (C/EBP). Activated
NF-kB, AP-1, and STAT correlated with enhanced expression of Nox
were detected within atherosclerotic lesions and in the vascular
wall of diabetic and hypertensive patients as well as in various
experimental animal models [39–42].
NF-kB, AP-1, and STATs are master regulators of numerous
genes linked to vascular inﬂammation and remodelling, the dif-
ferentiation of circulating immune cells and resident vascular cells.
Several redox-sensitive pathways, including Nox-derived ROS,
have been demonstrated to directly or indirectly affect the acti-
vation of these transcription factors in various cell types following
the exposure to cytokines, chemokines, growth factors, vasoactive
agents, and modiﬁed lipid and lipoproteins [43]. Hence, under-
standing the link between pro-inﬂammatory and redox signalling
pathways attracts continual interest and is a matter debate in the
ﬁeld of cardiovascular biology and medicine.
The implication of NF-kB in the regulation of Nox transcription
was initially demonstrated in murine macrophages [44]. In these
cells, interferon γ (IFNγ)/lipopolysaccharide (LPS)-induced
gp91phox (Nox2) expression was found to be mediated by acti-
vated NF-kB through direct transcription factor-gene promoter
interaction mechanisms. In addition, the expression levels of the
cytosolic regulatory component p47phox and of the essential
subunit p22phox were mediated by NF-kB-related pathways in
response to pro-inﬂammatory conditions. A similar pattern of NF-
kB-dependent transcriptional mechanisms of phagocyte-type Nox
regulation was further demonstrated in tumor necrosis factor α
(TNFα)-treated human monocytes [45]. Previously, we have found
several highly conserved NF-kB binding sites within the promoter
regions of the human genes coding for Nox1, Nox4, and p22phox
subunits, and that NF-kB inhibition reduced the IFNγ/TNFα-up-
regulated Nox activity and expression in human aortic smooth
muscle cells (SMCs) [46,47]. In contrast, despite the presence of
several NF-kB sites within the human Nox5 gene promoter, we
could not identify direct chromatin interactions. Nonetheless, the
fact that Nox5 gene and protein expression levels were sig-
niﬁcantly reduced in IFNγ-treated SMCs, suggests the existence of
an indirect transcriptional mechanism in the regulation of Nox5
expression.
Activation of AP-1 transcription factor has also been linked to
vascular response to injury. AP-1 is phosphorylated via multiple
mechanisms involving members of the mitogen-activated protein
kinase (MAPK) family such as extracellular signal-regulated pro-
tein kinase (ERK)1/2, c-Jun amino terminal kinase (JNK), p38
MAPK, and exerts its pro-inﬂammatory, hypertrophic and hyper-
plastic effects by activating various targets genes [48,49]. Based on
the fact that proinﬂammatory stimuli activate both AP-1 and Nox,
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of Nox-derived ROS and AP-1 activation are interrelated. We have
demonstrated before that AP-1 physically interacts with the pro-
moter of the human CYBA gene that codes for p22phox essential
subunit in angiotensin II (Ang II)/TNFα-stimulated human aortic
SMCs. Pharmacological inhibition of various MAPK or direct
blockade of AP-1-dependent transcriptional responses by decoy
oligodeoxynucleotides (ODN) abolished the Ang II/TNFα-induced
Nox1, Nox4, p22phox, p47phox, and p67phox mRNA expression
levels and ROS formation in human vascular SMCs [50]. Direct
DNA-AP-1 interaction was detected in the promoter of human
Nox5 gene in IFNγ-exposed vascular SMCs [51]. A similar AP-1-
dependent transcriptional regulatory mechanism has been in-
dicated for the rat Nox1 gene [52]. These data demonstrate that
AP-1 is an important regulator of Nox expression and function in
various pathological states.
Janus kinase (JAK)/STAT signalling pathway plays a major role
in mediating pro-inﬂammatory and immune responses. In cardi-
ovascular diseases, members of the STAT transcription factor fa-
mily regulate important genes linked to vascular inﬂammation.
STAT activation is an essential pathogenic mechanism leading to
SMC hypertrophy and hyperplasia. We have previously reported
that IFNγ-activated JAK regulates Nox expression and function in
human aortic SMCs. In addition, STAT1 and STAT3 physically in-
teracted with the promoter of human Nox1, Nox4, and Nox5 genes
via highly conserved gamma activated sequences (GAS). Moreover,
transient overexpression of STAT1/STAT3 led to a marked up-reg-
ulation of the luciferase levels under the control of the promoters
of human CYBA (coding for p22phox), NCF1 (coding for p47phox),
and NCF2 (coding for p67phox) genes, whereas the decoy ODN-
based blockade of STAT1 or STAT3 activities reduced their tran-
scriptional activation [53]. Moreover, pharmacological inhibition
of JAK2 by tyrphostin AG490 reduced the Nox activity and ex-
pression of Nox1, Nox2, and Nox4 in the aorta of hypercholester-
olemic ApoE-deﬁcient mice, a condition that was associated with a
signiﬁcant reduction of atherosclerotic plaque formation [17].
These results clearly support the implication of JAK/STAT signalling
in regulation of Nox and the ensuing ROS production in the vas-
cular cells exposed to pro-inﬂammatory conditions.
Evidence has accumulated suggesting that cytokine-induced
activation of non-STAT signalling pathways such as CCAAT/en-
hancer-binding proteins (C/EBP), regulate important aspects of
vascular dysfunction in atherosclerosis [54,55]. C/EBP transcription
factors belong to the basic-leucine zipper (bZip) transcription
factor family and regulate the expression of a number of genes
related to cellular proliferation and differentiation, immune and
inﬂammatory responses, such as cytokines, chemokines, acute
phase proteins and immunoglobulins [56,57]. In a previous study
we have demonstrated that high glucose-induced nuclear trans-
location and activation of C/EBPα, C/EBPβ, and C/EBPδ is mediated
by activated MAPK in human endothelial cells (ECs) [58]. Dose-
dependent increase in C/EBPα, C/EBPβ, and C/EBPδ activation and
protein expression levels was detected in human aortic SMCs ex-
posed to IFNγ. These data indicate that the activation of C/EBP
transcription factors correlates with the severity of the in-
ﬂammatory stress in these cells. In addition, we have found that C/
EBPα, C/EBPβ, and C/EBPδ regulate Nox1, Nox4, and Nox5 by direct
transcriptional mechanisms involving DNA-transcription factor
interactions [59]. These data are in good agreement with the for-
mer ﬁndings about the implication of C/EBPδ in mediating the
overactivity of CYBA gene promoter in hypertensive subjects car-
rying the GG genotype of the CYBA – 930A/G polymorphism [60].
Besides human Nox, the up-regulation of Nox1 by LPS has been
shown to be mediated by C/EBPβ and C/EBPδ in mouse macro-
phages [61].
Besides NF-kB, AP-1, STAT, and C/EBP, other pro-inﬂammatoryand vascular remodelling-promoting transcription factors, namely
activating transcription factor-1 (ATF-1), Ets-1, E2F, have been
implicated in the regulation of vascular Nox [62–64]. Based on the
fact that NF-kB, AP-1, and STAT transcription factors are redox-
sensitive, the existence of a positive feed-back loop whereby Nox-
derived ROS contribute to self-upregulation should be considered.
Taken together, one can conclude that multiple alternative pro-
inﬂammatory transcription factors converge to Nox regulation in
cardiovascular cells. Yet, understanding the precise biological sig-
niﬁcance of the apparent redundant signalling pathways requires
further investigation.
Other than pro-inﬂammatory transcription factors, several ne-
gative regulators of Nox expression have been demonstrated, such
as members of the peroxisome proliferator-activated receptor
(PPAR) family, which comprises 3 major isoforms, namely, PPARα,
PPARβ/δ, and PPARγ. These receptors function as ligand-activated
transcription factors following their dimerization with the retinoid
X receptor (RXR). PPARs control the expression of a large number
of genes that are involved in energy homeostasis and fatty acid
and glucose metabolism [65]. Compelling evidence exist that se-
lective activation of the various PPAR isotypes by synthetic ago-
nists negatively regulate Nox expression and activity, and reduce
inﬂammation in a number of clinical and experimental models of
cardiovascular diseases [66]. Nevertheless, the precise molecular
mechanisms supporting the antioxidant and anti-inﬂammatory
effects of PPARα, PPARβ/δ, and PPARγ agonists are not entirely
clear [67,68]. Conversely, it was shown that genetic ablation of
PPARα could abolish hypertension and attenuate atherosclerotic
plaque development in mice [69]. An interesting up-regulatory
mechanism of Nox expression and activity by PPARα agonists has
been identiﬁed in human and mouse macrophages, and a sig-
niﬁcant reduction in Nox activity and expression was detected in
macrophages of PPARα-deﬁcient mice. These reports indicate that
Nox-derived ROS may elicit anti-inﬂammatory activities by indu-
cing the formation of endogenous PPARα ligands, such as lipid
peroxidation products that are generated following degradation of
oxidized low-density lipoprotein [70]. Activation of Nox by PRARα
agonists was demonstrated in mouse embryonic stem cells and
was implicated in the process of cardiomyogenesis [71]. These data
show the need to delineate the relationship among PPARs and Nox
and the actual function of PPARs in the vasculature [72]. In addi-
tion, it is not known whether Nox subtypes are direct targets of
PPARs or whether their expression is indirectly affected. Several
lines of evidence support the concept that activation of PPARs
down-regulate the expression levels and also negatively interfere
by direct protein–protein interactions in the activation of several
pro-inﬂammatory transcription factors such as NF-kB, AP-1, and
STAT [73]. Based on the fact that NF-kB, AP-1, and STAT1/3 are
important regulators of Nox it can be hypothesized that the effects
of PPAR agonists on Nox expression and activity in vascular
pathologies are partially mediated by such negative regulatory
interactions.
Although numerous data related to the role of synthetic PPAR
agonizts exist, less is known about the nature of endogenous li-
gands that mediate these processes. It has been suggested that
oxidative derivatives of the fatty acids might serve as such ligands.
Emerging evidence indicate that at low and physiological levels
lipid peroxidation products of polyunsaturated fatty acids (PUFAs),
namely 4-hydroxy-2E-hexenal (4-HHE), 4-hydroxy-2E-nonenal (4-
HNE), and 4-hydroxy-2E,6Z-dodecadienal (4-HDDE), function as
natural endogenous activators for various PPAR isotypes [74–76].
We have recently found that high glucose induced the synthesis of
lipid peroxidation-based endogenous ligands for PPARα and
PRARβ/δ in human aortic SMCs [77]. Moreover, we have demon-
strated that high glucose-increased expression and function of Nox
is mediated by 4-HNE-activated PPARα and PPARβ/δ. Interestingly,
Fig. 2. Concept diagram depicting the potential transcriptional regulation of Nox by transcription factors and epigenetic mechanisms in vascular/immune cells in response to
cardiovascular risk factors. Activation of speciﬁc protein kinases/phosphatases leads to the activation of speciﬁc pro-inﬂammatory transcription factors (e.g., NF-kB, AP-1,
STAT1/3, and C/EBP) that regulate the expression of various Nox subtypes by direct and indirect mechanisms. Enhanced Nox-derived ROS formation induces oxidative stress
that triggers pro-inﬂammatory and oxidative processes in the vasculature. Alternative to the classical pro-inﬂammatory pathway of Nox activation, various lipid peroxidation
products (e.g., 4-HNE, 4-HDDE) generated via enzymatic or non-enzymatic mechanisms may function as natural endogenous ligands for PPARs. Activated PPARα or PPARβ/δ
act as negative regulators of pro-inﬂammatory pathways by interfering with NF-kB, AP-1 or STAT1/3 signalling. PPAR-mediated Nox up-regulation and ROS formation
contribute to the generation of lipid peroxidation products with PPARα or PPARβ/δ-activating functions. Activation of PPARs by synthetic agonists may compensate the
exacerbated pro-inﬂammatory and oxidative reactions in response to vascular insults. The diagram illustrates that several epigenetic mechanisms namely, histone acet-
ylation (hyperacetylation of nucleosomal histones or acetylation of pro-inﬂammatory transcription factors) and micro RNA (i.e., down-regulation of miRNA-25) differentially
regulate Nox4 expression and activity.
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imal promoters indicated the absence of typical PPAR elements
(PPRE) suggesting that PPARα and PPARβ/δ regulate Nox expres-
sion via indirect transcriptional mechanisms [77]. Of particular
importance is that all PPARs could regulate the expression of the
target genes by interacting with an intermediate transcription
factor such as Sp1 [78,79]. In good agreement with these ob-
servations are our previous studies on the ability of Sp1 to form
complexes with the promoter of Nox5 gene in human vascular
SMCs exposed to pro-inﬂammatory conditions, whereas several
highly conserved Sp1 elements were identiﬁed by in silico analysis
in the promoters of human Nox1 and Nox4 genes [51,77]. Our data
demonstrate the existence of a novel “lipid peroxidation products–
PPARs–Nox axis” as an alternative mechanism of Nox regulation in
diabetes. Also, this study highlights a novel redox sensing function
of the PPAR family in vascular cells in diabetes. A schematic con-
ceptual depiction of the crosstalk among pro-inﬂammatory tran-
scription factors and PPARs converging to Nox regulation is pre-
sented in Fig. 2.
Hypoxia represents a key major pathological event leading to
structural and functional changes in the cardiovascular system.
Up-regulation of Nox expression and activity under hypoxic con-
dition has been observed in various experimental settings, both in
vitro and in vivo [80]. Hypoxia-induced transcriptional responses
are mediated by a speciﬁc family of transcription factors named
hypoxia-inducible factors (HIF-1α, HIF-2α, and HIF-3α) whose
expression and function is tightly regulated by the level of mole-
cular oxygen. Moreover, the expression of various HIF isoforms,
such as HIF-1, has been reported to be up-regulated by ROS, pos-
sible generated by activated Nox, and oxidative stress-activated
pro-inﬂammatory transcription factors (e.g., NF-kB) [81,82].
Among the various Nox subtypes, the transcription of Nox4 has
been shown to be directly regulated by HIF-1α in pulmonary ar-
tery SMCs under hypoxic conditions [83]. Similarly, HIF-1α-in-
duced Nox2 transcription has been indicated as an important
mechanism of angiogenesis triggered by Nox-derived ROS [84].Thus, the induction of Nox expression by HIF-1α represents an
important compensatory feed-back mechanism that maintains the
physiologic level of ROS in cells after prolonged and intermittent
hypoxia.Epigenetic regulation of Nox enzymes
Recent evidence indicates that in addition to transcription
factors and their up-stream regulators (i.e., receptors, protein ki-
nases/phosphatases); dysregulation of epigenetic mechanisms
plays a major role in the pathoetiology of cardiovascular diseases
[85–89]. In particular, it has been demonstrated that epigenetic
pathways are implicated in the regulation of Nox expression and
function in various cell types [90]. Three major epigenetic systems
exist, namely DNA methylation, posttranslational modiﬁcation of
nucleosomal histones, and non-coding RNA [23].
DNA methylation of cytosine residues at the C5 position by DNA
methyltransferases represents the major mechanism of gene si-
lencing in the genome. Thus, aberrant methylation of the CpG is-
lands/shores and even CpG sites in the promoters/enhancers of
target genes may repress gene expression. The expression of
protein-encoding transcripts for Nox1, Nox2, Nox4, and Nox5
subtypes has been demonstrated in all vascular cells by means of
different mRNA expression assays. Hitherto, the direct implication
of DNA methylation in the regulation of Nox subtypes expression
in the vascular cells has not been demonstrated yet. Presumably,
the induction of several Nox subtypes under certain pathological
states is mediated by transcription-dependent mechanisms. Still,
the silencing of Duox1 and Duox2 gene expression by hy-
permethylation of the CpG islands present within the promoter
regions of both genes was demonstrated in human lung cancer
cells [91].
Post-translational modiﬁcations of nucleosomal core histones
(H2A, H2B, H3, and H4) at conserved lysine residues located on the
NH2-terminus regions are catalyzed by specialized enzymes and
S.-A. Manea et al. / Redox Biology 5 (2015) 358–366 363include acetylation, methylation, phosphorylation, and SUMOyla-
tion. Changes in chromatin conformation due to post-translational
modiﬁcation of histones modulate the accessibility of transcription
factors to their cognate DNA elements thus affecting gene ex-
pression. As a general principle, speciﬁc histone modiﬁcations
induce the transition from a transcriptional silent chromatin
(heterochromatin) to a transcriptional active chromatin (eu-
chromatin). Yet, multiple histone markers have been related to
gene expression and repression. Consequently, histone modiﬁca-
tions occurring within the enhancer/promoter region can induce
or repress the expression of the target gene [92,93].
Histone acetylation represents one of the major epigenetic
mechanisms regulating gene expression, and it generally triggers
transcriptional activation. An overall increase in cellular histone
acetylation was demonstrated in several models of cardiovascular
disorders, including atherosclerosis, hypertension, coronary heart
disease, cardiomyopathy, and heart failure [94–99]. The histone
acetylation state is regulated by two groups of specialized epige-
netic enzymes, namely histone acetyltransferases (HAT) and his-
tone deacetylases (HDAC). Thus far two types of HAT have been
described, namely type A (i.e., p300/CBP, GNAT, MYST, Basal TF,
and NRCF) and type B (HAT1, HAT2, HAT4, HatB3.1, and Rtt109).
The HDAC family is divided into four major classes, speciﬁcally
zinc-dependent class I (HDAC-1, -2, -3, and -8), zinc-dependent
class II (HDAC-4, -5, -6, -7, -9, and -10), NAD(þ)-dependent class
III (SIRT-1 to -7), and zinc-dependent class IV (HDAC11). Members
of the HAT and HDAC family display a speciﬁc pattern of cellular
expression and compartmentalization and are responsible for
precise biological activities. Most isotypes are located within the
nucleus whereas others elicit their function in the cytoplasm.
Evidence exist that selective members of either HAT and HDAC can
be imported into the nucleus from the cytoplasm and vice versa.
Of particular importance is that some HAT/HDAC isoforms can act
on non-histone proteins such as transcription factors and tran-
scriptional co-activators/repressors thereby affecting their func-
tion [99].
Pharmacological inhibitors of HDAC class I and II have emerged
as important alternative anti-cancer agents (clinical trials phase 1–
3) [100–102]. Interestingly, it has been demonstrated that HDAC
inhibitors efﬁciently reduce neointima hyperplasia and prevent
ischemia/reperfusion injury in the failing hearts [103–105]. Thus,
member of the HDAC family may be important therapeutic targets
in various cardiovascular pathologies. Interestingly, it has been
shown that pharmacological inhibition of HDAC reduces the
transcriptional activity and expression of Nox4 in human ECs
[106]. Based on the fact that histone acetylation promotes tran-
scriptional activation of the genes, these data put into a new light
the role of histone acetylation in the regulation of gene expression.
The authors elegantly showed that increased acetylation of his-
tones following the exposure of the cells to diverse HDAC in-
hibitors (e.g., scriptaid, suberoylanilide hydroxamic acid, and tri-
chostatin A) prevented the binding of AP-1 transcription factor and
RNA polymerase 2A to the promoter of the human Nox4 gene.
Similar ﬁndings were reported in human pulmonary ECs, in which
the gene and protein expression levels of Nox4 were signiﬁcantly
reduced by HDAC class I inhibitors [107]. Besides histone hyper-
acetylation, it has been demonstrated that acetylation of non-
histone proteins such as transcription factors (e.g., NF-kB, AP-1)
and transcriptional co-activators/repressors [108,109] may de-
termine either transcriptional activation or repression of the target
genes. Reportedly, activation of SIRT1, a class IV HDAC, displayed
anti-aging and anti-oxidant cardiovascular effects partially by
down-regulation of Nox-derived ROS production [109,110]. Inter-
estingly, it has been indicated that valproic acid, a potential HADC
inhibitor, elicits pro-oxidant effects in the cancer cells [111]. It is
yet to be investigated to what extent the dysregulation of histoneacetylation inﬂuences the expression and function of Nox subtypes
in other vascular cells or immune cells interacting with the blood
vessels. Nevertheless, evidence is accumulating that Nox-derived
ROS play a major role in histone modiﬁcation and chromatin
conformational changes, thus inﬂuencing key biological activities
and pathological manifestations [112–115].
Non-coding RNAs are important regulators of gene expression.
MicroRNAs (miRNAs) are a family of endogenous short (22–25 nt),
non-coding RNAs that negatively control gene expression at the
post-transcriptional level by binding to speciﬁc sequences located
within the 3′UTR of target mRNAs. Several miRNAs (e.g., miRNA-
21, miRNA-210, miRNA-34a, and miRNA-146a/b) have been shown
to be expressed differentially in the stable plaque versus unstable
plaque. In addition, it was shown that speciﬁc miRNA expression
patterns may predict long-termed cardiovascular events and sev-
eral miRNA-dependent mechanisms are directly linked to the pa-
thophysiology of cardiovascular diseases [116]. Yet, the precise role
and the associated molecular mechanisms of Nox regulation by
miRNAs are scantly elucidated. Based on the fact that miRNA ne-
gatively regulate the gene expression by post-transcriptional me-
chanisms, it has been suggested that Nox expression is tightly
regulated by several miRNAs under physiological conditions. In
contrast, down-regulation or repression of particular Nox-speciﬁc
miRNAs may lead to the up-regulation of oxidase complex in
various pathological states. In the line with hypothesis, it has been
demonstrated that miRNA-25 directly targets the 3′UTR of the
human Nox4 gene. Down-regulation of miRNA-25 expression as
observed under various pathological conditions (diabetes, hy-
percholesterolemia) has been implicated as important post-tran-
scriptional regulatory mechanism leading to Nox4 up-regulation
and consequent ROS production [117,118]. Besides direct post-
transcriptional regulation of Nox by miRNAs, emerging evidence
indicate that ROS, possibly generated by activated Nox regulate the
expression of several miRNAs thus contributing to the main-
tenance of vascular homeostasis or controlling key mechanisms in
various pathologies [119].Conclusions
Nox expression and function is regulated via multiple me-
chanisms. The data summarized in this review attest to a complex
interplay among transcription factors, co-activators/-repressors,
nuclear receptors, and epigenetic mechanisms converge to Nox
up-regulation in several cardiovascular disorders. Thus, under-
standing mechanisms and revealing the signalling molecules re-
sponsible for the increased expression and activation of Nox that is
associated with the onset and development of cardiovascular
dysfunction may contribute to the prevention and treatment of
cardiovascular diseases.Conﬂicts of interest
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